Drug Eluting Stent Global Market Report 2026

A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.

The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.

Tariffs are impacting the drug eluting stent market by increasing costs of imported metal scaffolds, drug compounds, and precision manufacturing equipment used in stent production. These effects are most evident across polymer-based and biodegradable scaffold segments, particularly in regions dependent on cross-border medical device supply chains such as Asia-Pacific and Europe. Higher tariffs have moderately increased procurement costs for hospitals and specialty clinics. At the same time, tariffs are encouraging local manufacturing, supplier diversification, and regional production investments, supporting long-term supply chain resilience.

The drug eluting stent market research report is one of a series of new reports from The Business Research Company that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug eluting stent market size has grown strongly in recent years. It will grow from $8.26 billion in 2025 to $8.94 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of coronary artery disease, growth in percutaneous coronary intervention procedures, rising incidence of lifestyle-related cardiovascular conditions, expansion of cardiac catheterization labs, improved clinical outcomes compared to bare-metal stents.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growing aging population, increasing demand for minimally invasive cardiac treatments, rising awareness of advanced stent technologies, expansion of specialty cardiac clinics, increasing healthcare expenditure on cardiovascular care. Major trends in the forecast period include rising adoption of biodegradable polymer stents, growing preference for polymer-free drug-eluting stents, increasing use in complex coronary interventions, shift toward long-term restenosis prevention, rising demand for improved drug release control.

The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stent market going forward. Coronary heart disease (CHD) is a condition where the coronary arteries become narrowed or blocked due to plaque buildup, potentially leading to severe complications such as a heart attack or chest pain. Coronary heart disease is increasing due to sedentary lifestyles, poor diets, aging populations, and heightened awareness. Drug-eluting stents (DES) benefit coronary heart disease by effectively opening narrowed or blocked coronary arteries and releasing medication that helps prevent re-narrowing (restenosis) of the artery. For example, in August 2025, according to the National Center for Biotechnology Information, a US-based government agency, between 2025 and 2050, cardiovascular disease is projected to rise significantly, with prevalence increasing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, resulting in an estimated 35.6 million cardiovascular deaths in 2050, up from 20.5 million in 2025. The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stench market.

Major companies operating in the drug-eluting stent market are focusing on developing innovative products, such as low-profile, high-flexibility stents, to improve deliverability in complex coronary anatomies and enhance patient outcomes. A low-profile, high-flexibility stent is a drug-eluting stent designed with a reduced crossing profile and enhanced flexibility, enabling it to navigate narrow, tortuous, or calcified coronary arteries more easily while maintaining effective drug delivery to prevent restenosis. For example, in May 2024, Abbott Laboratories, a US-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra features a novel stent design that provides best-in-class deliverability with significantly reduced crossing force compared to competitors. It also includes a thinner balloon and an optimized MULTI LINK structure to enhance flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Additionally, it offers a wide expansion range, allowing precise treatment even when vessel diameters vary along the lesion, enabling interventional cardiologists to address complex, calcified, or difficult-to-reach lesions with improved precision and safety.

In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Eluting Stent Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug eluting stent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug eluting stent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug eluting stent market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Polymer-Based; Polymer-Free
• 2) By Drug: Sirolimus; Paclitaxel; Zotarolimus; Everolimus; Biolimus; Other Drugs
• 3) By Scaffold: Cobalt-Chromium; Platinum-Chromium; Nitinol; Biodegradable; Other Scaffolds
• 4) By Application: Coronary Diseases; Peripheral Vascular Diseases
• 5) By End-User: Hospitals; Specialty Clinics
• Subsegments:
• 1) By Polymer-Based: Durable Polymer Drug-Eluting Stents; Biodegradable Polymer Drug-Eluting Stents
• 2) By Polymer-Free: Bare-Metal Stents With Drug Coating; Other Polymer-Free Drug-Eluting Stents
• Companies Mentioned: Abbott Laboratories; Boston Scientific Corporation; Medtronic plc; Terumo Corporation; BIOTRONIK SE & Co KG; Biosensors International Group Ltd; MicroPort Scientific Corporation; Lepu Medical Technology Beijing Co Ltd; Meril Life Sciences Pvt Ltd; Sahajanand Medical Technologies Pvt Ltd; Alvimedica Medical Technologies; Balton Sp z oo; Cordis (Cardinal Health) DES Manufacturing; Shandong JW Medical Systems Ltd; Sino Medical Sciences Technology Inc; STENTYS SA; Relisys Medical Devices Ltd; Translumina GmbH; Eurocor GmbH; Elixir Medical Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.